Loading…
Loading…
PEAR (Pear Therapeutics, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
PEAR does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for PEAR and 80,000+ other tickers.
See exactly how PEAR's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PEAR and 80,000+ other tickers.
Pear Therapeutics, Inc. is a commercial-phase medical company focused on inventing and distributing digital therapeutics. Its current offerings include reSET, which addresses substance use disorders involving alcohol, cannabis, cocaine, and stimulants; reSET-O, prescribed alongside buprenorphine for opioid use disorder; and Somryst, a digital solution for chronic insomnia. Beyond these marketed therapies, the company maintains a robust development pipeline of 14 prospective products. These investigational treatments span various therapeutic areas, encompassing psychiatry, neurology, and…
All 55 episodes are now live of America's first brand co-produced feature-length microsoap produced by dentsu Entertainment and Pixie USA LOS ANGELES, Feb. 12, 2026 /PRNewswire/ -- Native, a clean beauty and personal care brand, P&G Studios, a division of Procter & Gamble, and dentsu Entertainment, a division of dentsu, today announced the official launch of The Golden Pear Affair the first brand co-produced feature-length "microsoap" in the US. Produced by Pixie USA, and directors Kim Miller and Kristen Brancaccio, the microseries delivers a complete, cinematic story in bite-sized episodes designed for the vertical, mobile-first era.
Pear Therapeutics (NASDAQ: PEAR ) stock is falling on Friday after the company's recent bankruptcy filing continues to weigh on its shares. Pear Therapeutics announced its bankruptcy filing while markets were closed for Black Friday.
Pear Therapeutics (NASDAQ: PEAR ) stock is climbing higher on Tuesday despite the company's plans to explore strategic alternatives. That news was first announced by the company before markets opened on Friday.
The heavy selling pressure might have exhausted for Pear Therapeutics, Inc. (PEAR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Pear is focusing on its established substance abuse products now, putting development on a hold. Performance has been good into onboarding payors that have good coverage in markets where substance abuse is a problem.